Fibrocell Science, Inc. Form 8-K June 19, 2014

# **UNITED STATES**

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K **CURRENT REPORT** Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2014 FIBROCELL SCIENCE, INC.

(Exact name of registrant as specified in its charter)

Delaware (State or Other Jurisdiction of Incorporation)

001-31564 (Commission File Number)

87-0458888 (I.R.S. Employer Identification No.)

405 EAGLEVIEW BLVD., EXTON, PA 19341


(Address of Principal Executive Office) (Zip Code)

# Edgar Filing: Fibrocell Science, Inc. - Form 8-K (484) 713-6000

(Registrant s telephone number, including area code)

#### N/A

(Former name or former address, if changed since last report)



### Edgar Filing: Fibrocell Science, Inc. - Form 8-K

| Item | 1.01 | Entry | into a | Material | <b>Definitive</b> | Agreement. |
|------|------|-------|--------|----------|-------------------|------------|
|      |      |       |        |          |                   |            |

On June 17, 2014, Fibrocell Science, Inc., a Delaware corporation (the *Company*), issued a press release announcing that it had entered into two Exclusive License Agreements (the *Agreements*) with The Regents of the University of California, a California corporation (*UC*), each dated as of June 13, 2014 and effective as of June 1, 2014. A copy of such press release is attached as Exhibit 99.1 to this report.

Under the terms of one of the Agreements (the *BMP2 Agreement*), UC granted to the Company an exclusive, sublicensable right and license to use certain patent rights developed in collaboration between UC and the Company relating to the use of human skin cells to produce Bone Morphogenetic Protein (BMP2) for use in osteogenic therapies. In consideration of the license granted under the BMP2 Agreement, the Company will pay to UC a license issue fee, certain one-time milestone payments, a license maintenance fee, earned royalties on net sales of all licensed products (including sales by sublicensees and affiliates) and a percentage of amounts received from sublicensing activities. The Company is subject to minimum annual royalty payments to UC beginning after first commercial sale of a licensed product.

Under the terms of the second of the Agreements (the *Genomic Stability Agreement*), UC granted to the Company an exclusive, sublicensable right and license to use certain patent rights developed in collaboration between UC and the Company relating to media that promotes genomic stability in induced pluripotent stem cell cultures for all research and commercialization purposes. In consideration of the license granted under the Genomic Stability Agreement, the Company will pay to UC a license issue fee, certain one-time milestone payments, a license maintenance fee, earned royalties on net sales of all licensed products (including sales by affiliates) and a percentage of amounts received from sublicensing activities. The Company is subject to minimum annual royalty payments to UC beginning after first commercial sale of a licensed product.

Each of the Agreements terminates on the earliest of (i) the expiration date or abandonment of the last-to-expire patent or last to-be-abandoned patent application licensed under such Agreement, (ii) at the option of UC, an uncured default by the Company under such Agreement or the failure by the Company to meet certain development and/or commercialization milestones under such Agreement, and (iii) the prior written notice given by the Company.

The foregoing is a summary of the material terms of the Agreements and does not purport to be complete. You should read the complete Agreements, which shall be attached as an exhibit to the Company s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2014. The Company will seek confidential treatment for certain terms of the Agreements at the time of filing such Quarterly Report.

#### Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit
No. Description

99.1 Press Release dated June 17, 2014

# Edgar Filing: Fibrocell Science, Inc. - Form 8-K

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

### FIBROCELL SCIENCE, INC.

By: /s/ Gregory Weaver

Gregory Weaver Chief Financial Officer

Date: June 19, 2014

3

# Edgar Filing: Fibrocell Science, Inc. - Form 8-K

## EXHIBIT INDEX

| Exhibit<br>No. |                                   | Description |
|----------------|-----------------------------------|-------------|
| 99.1           | Press Release dated June 17, 2014 |             |
|                |                                   | 4           |